Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingjun Zhi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Endocrine|June 25, 2022
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinomaSebastian E Serfling, Yingjun Zhi, Felix Megerle, et al.
Endocrine|December 22, 2023
[<sup>18</sup>F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patientsYingjun Zhi, Takahiro Higuchi, Stephan Hackenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activityMichael Gernert, Marc Schmalzing, Hannah Labinsky, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|February 8, 2023
Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung CancerSebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Cancers|May 13, 2026
Impact of Neuroendocrine Neoplasm-Specific Systemic Treatments on Somatostatin Receptors Expression and Function in Neuroendocrine Tumor CellsChristof Däubler, Clara Böttcher, Laura-Sophie Landwehr, et al.
Clinical Nuclear Medicine|March 3, 2025
Somatostatin Receptor-Directed Theranostics in EsthesioneuroblastomaYingjun Zhi, Sebastian E Serfling, Daniel Groener, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 29, 2023
Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [<sup>18</sup>F]FDGYingjun Zhi, Rudolf A Werner, Andreas Schirbel, et al.
Frontiers in Immunology|April 3, 2026
[<sup>18</sup>F]-FDG-PET/CT detects subclinical optic nerve inflammation in giant cell arteritisMichael Gernert, Marc Schmalzing, Matthias Fröhlich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2021
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [<sup>18</sup>F]FDG PET/CT and MRIChristian Linz, Roman C Brands, Olivia Kertels, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Endocrine|June 25, 2022
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinomaSebastian E Serfling, Yingjun Zhi, Felix Megerle, et al.
Endocrine|December 22, 2023
[<sup>18</sup>F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patientsYingjun Zhi, Takahiro Higuchi, Stephan Hackenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activityMichael Gernert, Marc Schmalzing, Hannah Labinsky, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Clinical Nuclear Medicine|February 8, 2023
Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung CancerSebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Cancers|May 13, 2026
Impact of Neuroendocrine Neoplasm-Specific Systemic Treatments on Somatostatin Receptors Expression and Function in Neuroendocrine Tumor CellsChristof Däubler, Clara Böttcher, Laura-Sophie Landwehr, et al.
Clinical Nuclear Medicine|March 3, 2025
Somatostatin Receptor-Directed Theranostics in EsthesioneuroblastomaYingjun Zhi, Sebastian E Serfling, Daniel Groener, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 29, 2023
Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [<sup>18</sup>F]FDGYingjun Zhi, Rudolf A Werner, Andreas Schirbel, et al.
Frontiers in Immunology|April 3, 2026
[<sup>18</sup>F]-FDG-PET/CT detects subclinical optic nerve inflammation in giant cell arteritisMichael Gernert, Marc Schmalzing, Matthias Fröhlich, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2021
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [<sup>18</sup>F]FDG PET/CT and MRIChristian Linz, Roman C Brands, Olivia Kertels, et al.
Pageof 2